Pharmatalkradio

Dr Roslyn Schneider, Global Patient Affairs Lead at Pfizer, speaks with Valerie Bowling, Executive Director, Patients as Partners, in a podcast interview on patients at the center of clinical research. Dr Schneider, better known as Roz, helps drive patient centricity and the integration of the patiemt voice throughout the development of medicines at Pfizer. She gives us a brief history of the evolution of the involvement of patients in clinical research, next steps, and how patients and industry can collaborate. Roz, together with Suzanne Schrandt, Director of Patient Engagement at the Arthritis Foundation, will co-chair the 5th annual Patients as Partners conference, March 15-16 at the Rittenhouse Hotel in Philadelphia. For more information, visit theconferenceforum.org.

DPharm Podcast Series #5 Reducing the Burden of Type 1 Diabetes through a Model of Democratized R&D Patient advocate star, Dana Lewis, founder of OpenAPS delivers a powerful session at DPharm on an idea to reduce the burden of type 1 diabetes with a smart system she created through open soucre. Learn how she drive the idea and creation of the "Self driving car for diabetes". The next DPharm conference is September 25-26 in Boston. DPharm reports on innovation and disruptive innovation to advance clinical trials and supports the community behind the movement. Speaker: Dana Lewis, Creator, Do-It-Yourself Pancreas System and Founder, OpenAPS Producer: Valerie Bowling, Executive Director, DPharm

 5th Annual Patients as Partners What to Expect Overview Podcast Officially approved by Patients Included, Patients as Partners is the only program in the US that truly demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. Taking place March 15-16 in Philadelphia, the focus of this year’s program is on turning discussion into action, and Kate Woda, the Conference Director has worked meticulously with the advisory board and members of the speaking faculty both in person and over the phone to make this happen. Valerie Bowling, Executive Director of the Conference Forum gives listeners an overview in a nutshell on what to expect. Co Chairs: Roslyn Schneider, MD Global Patient Affairs Lead, Pfizer Medical Suzanne Schrandt, JD (Newly confirmed!) Director, Patient Engagement, Arthritis Foundation Patient Keynote: Stefanie Joho, Cancer Survivor, Advocate and Consultant For more information, visit www.theconferenceforum.or

DPharm podcast series # 2  MIT Professor, Dina Katabi, PhD gave one of the best talks on in home non-intrusive patient monitoring at DPharm 2017 and provided a demo of technology that uses ambient radio signals to monitor a patient’s gait, falls, breathing, heart rate and even sleep, all without putting any sensor on the patient’s body. Find out how they have used the technology to redefine clinical endpoints and pushed clinical trials to the home. The next DPharm conference is September 25-26 in Boston. DPharm reports on innovation and disruptive innovation to advance clinical trials and supports the community behind the movement.  Speaker: Dina Katabi, PhD MacArthur Fellow, Andrew & Erna Viterbi Professor, MIT, and Director of MIT Center for Wireless Networks and Mobile Computing Producer: Valerie Bowling, Executive Director, DPharm

The Conference Forum presents a 1 day meeting on Immuno-Oncology Clinical Trial Operations, February 8th at the Roosevelt hotel in NYC. It’s part of the IO360 conference, which runs over three days from Feb 7th through the 9th.  The OPERATIONS portion of this conference is offered as a stand alone program.  This podcast gives a brief summary of what to expect. The morning provides first hand reporting on new trends and emerging technologies. The afternoon goes through 7 components including: the patient perspective, site management, 3rd parties, clinical supply chain, a PI perspective, data management and project management.  Many thanks to Andy Lee, SVP, Head of Global Clinical Trial Operations at Merck for his guidance on the topic and for bringing his team to help us understand the building blocks, providing a really unique insight into obtaining the necessary precision IO trial operations require.  For information, go to www.theconferenceforum.org

The 2nd annual Patients as Partners EU is the only conference in Europe that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. In this short podcast, Valerie Bowling, executive director at the Conference Forum gives a brief summary of what to expect at this conference and runs through the highlights.  Chairs: Tony Hoos, MD, PhD, MBA Head of Medical, Amgen Europe Andrew Garvey Global Patient Advocacy Lead, GlaxoSmithKline The premier event was attended by roughly 150 people and the program brings back: Accreditation by Patients Included “Ask the Patient” program to give attendees the opportunity to meet a group of individuals who’ve experienced a clinical trial.Attendee “Tool-Box” and an assortment of specially designed materials to help capture ideas. Patients as Partners EU is co-produced with industry, patient advocacy and government to establish a well-rounded program that addresses the needs of all stakeholde

If you are interested in hearing the 2017 drug delivery landscape year in review in 2017, please email service@tcfllc.org Chair of the Partnership Opportunities in Drug Delivery (PODD) event, Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche, presents an annual year-in-review of the drug delivery landscape from 2016. Dr Lueckel’s opening remarks are a highlight of PODD every year, and we’re excited to have her return as program chair for the 2018 event, coming up on October 17-18 in Boston. We will post Dr Lueckel's 2017 overview of the drug delivery market shortly.  About Dr Lueckel: Since end of 2014, Barbara leads the Research & Technologies Partnering (RTP) team belonging to the Innovation Partnering group in Roche Partnering. RTP team members lead evaluations & negotiations with biotech companies in an effort to enhance the discovery efforts of Roche’s Research & Early Development organization (pRED) across all of its therapeutic areas – either applying technology p

Pan American Games Champion, Olympian and World Championship silver medalist, Jennifer Goldsack, became a world-class athlete while working and studying at the University of Oxford. How did she do it? She recently shared her story with DPharm Director, Valerie Bowling, discussing the lessons she learned from her Olympic experience and how she uses them in her professional life at the Clinical Trials Transformation Initiative (CTTI). Ms Goldsack manages the development and implementation of Clinical Trials Transformation Initiative (CTTI) projects. In collaboration with team leaders, she creates project plans and budgets, and manages the implementation of those plans. She earned her master’s degree in chemistry from the University of Oxford, England, her masters in the history and sociology of medicine from the University of Pennsylvania, and her MBA from the George Washington University. Additionally, she is a certified Lean Six Sigma Green Belt and a Certified Professional in Healthcare Quality.  Ms Goldsa

Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including: Discovery / Preclinical ScienceTranslational ScienceClinical DevelopmentBusiness AspectsInvestor RelationsEmerging TechnologiesBiomarkers / DiagnosticsTrends in the Field Dr Axel Hoos, GSK and Dr James Gulley, NCI, together led the design of the 4th annual Immuno-Oncology 360° program to include 45 speakers and over 30 talks. Save the date: February 7-9, 2018 in New York City.

The Conference Forum is pleased to share a podcast featuring keynote speaker and world renowned customer service expert, Dr Chip Bell who spoke at the 6th annual DPharm: Disruptive Innovations to Advance Clinical Trials on the topic of service in clinical trials. To truly service our patients, we need to understand service together with science. Can service be a disrupter in clinical research? In this keynote, Dr Bell tells us how to think like a service industry, why it’s worth it for R&D and how to get started. Dr Bell gives the listener practical insights on how to give patients a great experience. Although this podcast is primarily focused on serving patients in clinical research, you will find that hospitals and physician offices/medical groups will also benefit. The 8th annual DPharm conference will continue to cover service, but through a patient perspective. DPharm 2018 takes place September 25-26 in Boston. For more information, www.theconferenceforum.org About Dr Chip Bell: Dr Bell is consid

Originally recorded during the 4th annual Patients as Partners US event held in Philadelphia, March 2017, Bristol-Myers Squibb’s Mary Stober-Murray moderates this multi-stakeholder panel to discuss what patients truly want when it comes to clinical care and patient involvement. Patients John Creveling, a Parkinson’s Foundation Research Advocate, and Deb Maskens from the International Kidney Cancer Coalition, join her and representing the industry perspective are Paul Graves from Takeda Pharmaceuticals and Dr Michelle Vichnin from Merck. Closing the gap between clinical care and patients wants/needs: • Ask patients what’s going on in their lives. • Ask patients what their goals are. • Because no one asks patients these questions, the result is they get care that’s aligned with what the doctor thinks is clinically relevant, even though it may be completely out of context to what is important to the patient. What patients want and how pharma can help: • Identify what patients and industry want respectively

Internationally recognized digital health expert, Donald Jones, MBA, Chief Digital Officer at Scripps Translational Science Institute, shares his insights on the digital clinical trial landscape and the urgent need to pair digitization with drug products for patients during his keynote address from the 2016 CMO Summit. The Chief Medical Officer Summit is designed for CMOs and R&D Leadership from small to mid-size life science companies. The 6th Annual CMO Summit will be held May 7-8, 2018, in Boston.                                                                                    

In this multi-stakeholder session from the 4th annual Patients as Partners US meeting, patients, advocates, industry and nonprofit organizations come together to discuss how they partnered and the outcomes of those partnerships. • What’s the roadmap? • What are the ways you have partnered with industry? • What are some best practices or rules of engagement? • How can the pharma industry better serve patient advocacy organizations? • How are we creating and ruthlessly maintaining transparency and trust? • Addressing global models of patient engagement • Big companies are working in global environment and the Patient Engagement issues are quite different culturally, whether it’s China, Japan, Asia. What are the unique challenges and opportunities in countries outside US and EU? Moderated by Lori Abrams, Director, Diversity and Patient Engagement, Bristol-Myers Squibb, panelists included: Stephanie Christopher, Program Manager, Patient Centered Benefit-Risk, Medical Device Innovation Consortium; Lauren M

Adapted from the 2016 Chief Medical Officer Summit keynote address, Dr Akshay Vaishnaw, who serves as EVP of R&D and CMO at Alnylam Pharmaceuticals, tackles the challenges and opportunities in pursuing a new therapeutic modality from its inception. The Chief Medical Officer Summit is designed for CMOs and R&D Leadership from small to mid-size life science companies. The 6th Annual CMO Summit will be held May 7-8, 2018, in Boston.

At the 2017 Partners Europe event in London, Nicholas Brooke, Chief Executive, Patient Focused Medicines Development (PFMD) and Jan Geissler, Director, European Patients’ Academy on Therapeutic Innovation (EUPATI) call on industry to partner with patients in the development and lifecycle of medicines. The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.  

Dr Axel Hoos, GSK, leads a panel discussion on Trends and Collaborations in the Immuno-Oncology Space, featuring Dr Ramy Ibrahim, VP and Head of R&D, Parker Institute for Cancer Immunotherapy; Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs, Cancer Research Institute; Dr Daniel Chen, VP, Global Head of Cancer Immunotherapy Development, Genentech; and David Wholley, MPhil, Director, Research Partnerships Division, Foundation for the National Institutes of Health. The 4th Annual IO360° conference will take place February 7-9, 2018 in New York City.

At the inaugural Patients as Partners Europe event, Duncan Arbour from inVentiv Health explores the ‘how’ and ‘when’ for involving patients within clinical and commercial to enhance the development and delivery of innovative therapies.  The patient voice as a strategic driver is being included much earlier in the development process than ever before. In this session, pharmaceutical, biotech and device companies will gain insight into the value of smarter patient integration. Key focus areas include: • The critical shift from drug-centric to patient-relevant • Pivotal patient touch points throughout clinical development and launch planning that will maximize both clinical and commercial outcomes • Positive impact of integration on efficiency and commercialization The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2n

Alastair Kent, Director of the Genetic Alliance UK, talks about how patients can and are influencing policy within the EU.  The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.

Originally presented during the business aspects plenary session at Immuno-Oncology 360° 2017, Dr Axel Hoos of GSK discusses business models for complex science.  Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. Dr Hoos returns as lead advisor, as well as moderating a talk called, "Investor Roundtable: The Role of IO within Large Pharma - Where Does it Stand?" with panelists from Citi, Atlas Venture, New Enterprise Associates, and SR One Ltd.

Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the translational science and new technologies session from 2017’s Immuno-Oncology 360° conference. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. About Dr Cesano: Alessandra Cesano, MD, PhD has served as CMO at nanoString since July 2015. Prior to joining the company, Dr Cesano was Chief Medical Officer at Cleave Biosciences, Inc. From 2008 to 2014, she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc, where she built and led the R&D groups, while providing the overall clinical vision for the organization. In addition, Dr Cesano has held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals.